Fusion Pharmaceuticals Inc. announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.
Dr. Bobilev joins Fusion from Checkmate Pharma, where he was vice president, head of clinical development until
the company's acquisition by Regeneron earlier in 2022. At Checkmate, he was responsible for clinical
development strategy for vidutolimod. Prior to Checkmate, Dr. Bobilev was vice president, head of clinical
development at Vedanta Biosciences. He previously held clinical development leadership roles with Tesaro and
Sanofi. Dr. Bobilev spent more than 10 years as a practicing medical and radiation oncologist.